Additionally, the overall markets have been soft, allowing shrewd investors to pick up PFE stock at a more attractive valuation. Since closing at $38.66 near January-end, PFE has dropped 6%. On a year-to-date basis, shares have gone …
Everyone is so concerned with the likes of Pfizer (PFE), Johnson&Johnson (JNJ), Novartis (NVS ... He took a large stake in Celator (CPXX) which had a focus on …
With a market-beating 3.5% yield, great range of new drugs and decent dividend growth since the recession, PFE stock has found its way into plenty of income-seekers portfolios. But the best is yet to come. Thanks to the new GOP tax …
And despite issuing better-than-predicted 2018 guidance, PFE stock fell as much as 2 percent in early morning trading. Heading into the earnings report, Pfizer shares were up 24 percent, matching the gains of the Standard & Poor's 500 …
It was a happening week for pharma stocks, Key developments this week included a new CAR-T deal for Pfizer PFE, successful study results from Pfizer, Lilly LLY and Allergan AGN and positive regulatory updates from AstraZeneca …
This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price. A question to answer is whether PFE’s current trading price of $35.38 reflective of the actual value of the large-cap?